DK3682241T3 - Pct og pro-adm som markører til monitorering af antibiotikabehandling - Google Patents

Pct og pro-adm som markører til monitorering af antibiotikabehandling Download PDF

Info

Publication number
DK3682241T3
DK3682241T3 DK18765658.2T DK18765658T DK3682241T3 DK 3682241 T3 DK3682241 T3 DK 3682241T3 DK 18765658 T DK18765658 T DK 18765658T DK 3682241 T3 DK3682241 T3 DK 3682241T3
Authority
DK
Denmark
Prior art keywords
adm
markers
pro
pct
antibiotic treatment
Prior art date
Application number
DK18765658.2T
Other languages
English (en)
Inventor
Darius Wilson
Original Assignee
Brahms Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59887051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3682241(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brahms Gmbh filed Critical Brahms Gmbh
Application granted granted Critical
Publication of DK3682241T3 publication Critical patent/DK3682241T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/26Infectious diseases, e.g. generalised sepsis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
DK18765658.2T 2017-09-13 2018-09-13 Pct og pro-adm som markører til monitorering af antibiotikabehandling DK3682241T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17190913 2017-09-13
PCT/EP2018/074724 WO2019053117A1 (en) 2017-09-13 2018-09-13 PCT AND PRO-ADM USED AS CONTROL MARKERS IN ANTIBIOTIC TREATMENT

Publications (1)

Publication Number Publication Date
DK3682241T3 true DK3682241T3 (da) 2022-05-16

Family

ID=59887051

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18765658.2T DK3682241T3 (da) 2017-09-13 2018-09-13 Pct og pro-adm som markører til monitorering af antibiotikabehandling

Country Status (10)

Country Link
US (1) US20200264199A1 (da)
EP (2) EP3682241B1 (da)
JP (2) JP7258860B2 (da)
CN (1) CN111094981B (da)
BR (1) BR112020004150A2 (da)
CA (1) CA3075442C (da)
DK (1) DK3682241T3 (da)
ES (1) ES2913298T3 (da)
WO (1) WO2019053117A1 (da)
ZA (1) ZA202001108B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3682241T3 (da) 2017-09-13 2022-05-16 Brahms Gmbh Pct og pro-adm som markører til monitorering af antibiotikabehandling
RU2724186C1 (ru) * 2020-01-23 2020-06-22 Наталья Борисовна Гусева Способ лечения детей раннего возраста с рецидивирующей инфекцией мочевой системы

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570703B1 (fr) 1984-09-26 1988-07-08 Commissariat Energie Atomique Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents
US4882733A (en) 1987-03-13 1989-11-21 Ford Aerospace Corporation Method and apparatus for combining encoding and modulation
FR2664699B1 (fr) 1990-07-13 1995-08-18 Cis Bio Int Procede d'amplification du signal d'emission d'un compose luminescent.
ES2401703T3 (es) * 2007-08-03 2013-04-23 B.R.A.H.M.S Gmbh Utilización de la procalcitonina (PCT) en la estratificación de riesgo y el pronóstico de los pacientes con una enfermedad primaria no infecciosa
EP2240466B1 (en) * 2008-01-08 2015-07-29 Merck Sharp & Dohme Limited Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
ES2536761T3 (es) * 2009-06-05 2015-05-28 B.R.A.H.M.S Gmbh Detección de infecciones bacterianas en individuos que padecen disnea
BR112012022509A2 (pt) * 2010-03-08 2017-09-26 Brahms Gmbh procalcitonina para o diagnóstico de infecções bacterianas e orientação de tratamento antibiótico em pacientes com queixas não específicas.
WO2012059477A1 (en) * 2010-11-01 2012-05-10 B.R.A.H.M.S Gmbh Prognosis and risk assessment of patients with non-specific complaints
US11067586B2 (en) * 2011-11-16 2021-07-20 Sphingotec Gmbh Adrenomedullin assays and methods for determining mature adrenomedullin
EP2637023A1 (en) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
SG10201800309SA (en) * 2013-03-20 2018-02-27 Sphingotec Gmbh Adrenomedullin to guide therapy of blood pressure decline
DK3682241T3 (da) 2017-09-13 2022-05-16 Brahms Gmbh Pct og pro-adm som markører til monitorering af antibiotikabehandling

Also Published As

Publication number Publication date
US20200264199A1 (en) 2020-08-20
JP7258860B2 (ja) 2023-04-17
BR112020004150A2 (pt) 2020-09-08
CA3075442A1 (en) 2019-03-21
EP3682241A1 (en) 2020-07-22
JP2023095851A (ja) 2023-07-06
CA3075442C (en) 2024-04-02
EP4027145A1 (en) 2022-07-13
WO2019053117A1 (en) 2019-03-21
CN111094981A (zh) 2020-05-01
WO2019053117A8 (en) 2021-01-21
RU2020111718A3 (da) 2022-02-01
ES2913298T3 (es) 2022-06-01
ZA202001108B (en) 2022-08-31
JP2020533603A (ja) 2020-11-19
CN111094981B (zh) 2024-04-16
RU2020111718A (ru) 2021-10-13
EP3682241B1 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
DK3676297T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK3600456T3 (da) Fremgangsmåde til sterilisering
DK3247371T3 (da) Fremgangsmåder til oprensning af cannabinoider, sammensætninger og kits dertil
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
DK3265947T3 (da) Fremgangsmåde og system til kryptering
DK3212189T3 (da) Substituerede chromaner og fremgangsmåde til anvendelse deraf
DK3328849T3 (da) 1,1,1-trifluor-3-hydroxypropan-2-yl-carbamat-derivater og 1,1,1-trifluor-4-hydroxybutan-2-yl-carbamat-derivater som magl-inhibitorer
DK3221306T3 (da) Heteroarylforbindelser som irak-inhibitorer og anvendelser deraf
DK3536685T3 (da) Bicyklisk-fusionerede heteroaryl- eller arylforbindelser og anvendelse deraf som irak4 inhibitorer
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
ES2972395T3 (es) Dispositivos de ligadura de tejidos
DK3129912T3 (da) Fremgangsmåde og system til sikring af data
DK3621960T3 (da) Thienpyridiner og benzothiophener, der er anvendelige som irak4-hæmmere
DK3672976T3 (da) Bcl-2-hæmmere
DK3663290T3 (da) Polymethinforbindelser og anvendelse deraf som fluorescerende markører
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
DK3406490T3 (da) Spildevandshåndteringssystem til køretøjer og tilhørende fremgangsmåde
DK3346056T3 (da) Rengøringssystem og fremgangsmåde
DK3313833T3 (da) Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3692009T3 (da) Biocementationsfremgangsmåde og system
DK3630744T3 (da) Pyrazol-magl-inhibitorer
DK3093809T3 (da) Systemer og fremgangsmåder til tilstandsmaskinforvaltning
DK3232555T3 (da) Fremgangsmåde, indretning og system til fordelt styring af undermodul
DK3282008T3 (da) Sporulationsfremgangsmåde for Bacillus bacterium